Surgery after neoadjuvant treatment for non-small cell lung cancer: Decision making and patient outcome

Thesis

Cover

Title pages

Contents

Chapter 1: Introduction

Chapter 2: Neoadjuvant (induction) erlotinib response in stage IIIA non-small cell lung cancer (NSCLC)

Chapter 3: Tumour response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer

Chapter 4: Is 18F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer?

Chapter 5: Soluble epidermal growth factor receptor (sEGFR) and carcinoembryonic antigen (CEA) concentration in patients with non-small cell lung cancer: Correlation with survival after erlotinib and gefitinib treatment

Chapter 6: Ligands of epidermal growth factor receptor and the insulin-like growth factor family as serum biomarkers for response to epidermal growth factor receptor inhibitors in patients with advanced non-small cell lung cancer

Chapter 7: Non-small cell lung carcinoma of the superior sulcus: Favourable outcomes of combined modality treatment in carefully selected patients

Chapter 8: Results of combined modality treatment in patients with non-small cell lung cancer of the superior sulcus and the rationale for surgical resection

Chapter 9: Concurrent high-dose radiotherapy with low-dose chemotherapy in patients with non-small cell lung cancer of the superior sulcus

Chapter 10: Discussion

Summary

Nederlandse samenvatting

Dankwoord

Portfolio

List of publications

Curriculum vitae

Stellingen